SVG 501
Alternative Names: SVG-501Latest Information Update: 19 Sep 2022
At a glance
- Originator SoVarGen
- Class Antidementias; Antisense oligonucleotides
- Mechanism of Action Protein biosynthesis modulators; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Alzheimer's disease
Most Recent Events
- 08 Sep 2022 SVG 501 is available for licensing as of 08 Sep 2022. http://www.sovargen.com/rd#section1
- 08 Sep 2022 Early research in Alzheimer's disease in South Korea (Parenteral) prior to September 2022 (SoVarGen pipeline, September 2022)